• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Pract

  2026-05-06

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) prevents proteolytic degradation during protein extraction without interfering with divalent cation-dependent workflows. It is appropriate for Western blotting, co-immunoprecipitation, and kinase assays, but should not be used where EDTA-sensitive metalloprotease inhibition is required.

• Stiripentol: LDH Inhibitor for Epilepsy & Metabolic Assays

  2026-05-06

  Stiripentol offers precise, noncompetitive LDH inhibition for advanced epilepsy and immunometabolic research. Its solubility profile and validated workflow parameters make it a trusted choice for dissecting lactate metabolism in cellular and animal models.

• Imatinib (STI571): Precision Kinase Inhibition Meets Next-Ge

  2026-05-05

  Explore Imatinib (STI571)'s role as a selective tyrosine kinase inhibitor in cancer biology research, with unique insights into advanced mass spectrometry imaging technologies. Discover protocol nuances, reference-backed best practices, and the evolving landscape of kinase pathway interrogation.

• Tolazoline in Functional Islet Assays: Assay Optimization &

  2026-05-05

  Explore the nuanced role of Tolazoline as an α2-adrenergic receptor antagonist in advanced islet function and airway research. This article delivers a protocol-focused, evidence-labeled guide for optimizing assay performance, grounded in recent mechanistic discoveries.

• Triacetin Digestion: Hepatic Metabolic Regulation via SCTG A

  2026-05-04

  This study clarifies the digestion and absorption pathway of triacetin, a short-chain triacylglycerol (SCTG), in a rat model. The work elucidates how triacetin-derived acetic acid modulates hepatic energy metabolism, offering new mechanistic insight into the metabolic roles of SCTGs and their potential as dietary modulators.

• CHIR 99021 Trihydrochloride: Orchestrating Organoid Diversit

  2026-05-04

  Explore how CHIR 99021 trihydrochloride, a potent GSK-3 inhibitor from APExBIO, is revolutionizing translational research by enabling dynamic control over stem cell fate and organoid diversity. This thought-leadership article blends mechanistic insight, experimental guidance, and strategic context—grounded in the latest literature—to help translational researchers optimize protocol design and unlock new biological complexity in organoid systems.

• Determining α2-Adrenergic Receptor Binding via Open-Tubular

  2026-05-03

  This study introduces an innovative open-tubular capillary electrochromatography (CEC) method with partial capillary coating to accurately quantify the binding constants between α2-adrenergic receptors and seven drug compounds. The approach minimizes protein consumption and supports high-throughput binding affinity assays, with implications for receptor-targeted pharmacology and compound screening.

• CCL7+ Macrophages and Immunotherapy Resistance in Colorectal

  2026-05-02

  This study reveals that CCL7-expressing tumor-associated macrophages (TAMs) drive resistance to immune checkpoint inhibitors in colorectal cancer (CRC) by modulating immune cell infiltration and function. Targeting CCL7 in TAMs enhances CD8+ T cell infiltration and boosts the efficacy of anti-PD-L1 therapy, providing a mechanistic rationale for new combination immunotherapy strategies.

• Indazole/Indole Glucagon Receptor Antagonists for Diabetes C

  2026-05-01

  This study introduces a new series of indazole- and indole-based glucagon receptor antagonists designed to improve glycemic control in type 2 diabetes models. By systematically modifying the core scaffold derived from MK 0893, the researchers identified compounds with potent in vitro activity and demonstrated oral efficacy in humanized mouse models.

• A23187, Free Acid: Advanced Insights for Calcium-Mediated Ap

  2026-05-01

  Explore how A23187, free acid—a potent calcium ionophore—enables precise modulation of intracellular calcium and apoptosis pathways. This article offers advanced assay design insights, practical protocol parameters, and a critical bridge between mechanistic depth and translational application.

• NUAK1/2 Inhibition Reduces Tau Ser356 Phosphorylation in Alz

  2026-04-30

  Taylor et al. (2024) reveal that phosphorylation of tau at Ser356, mediated by NUAK1, is closely linked to Alzheimer’s pathology and can be selectively lowered in human brain slice cultures using the NUAK1/2 inhibitor WZ4003. These findings highlight a mechanistic role for NUAK1 in tauopathy progression and offer a validated ex vivo approach for probing kinase-targeted interventions in neurodegenerative diseases.

• Canagliflozin: SGLT2 Inhibitor Workflows for Renal Research

  2026-04-30

  Canagliflozin, a potent SGLT2 inhibitor, enables researchers to probe both glucose metabolism and mitochondrial remodeling in diabetic kidney models. This guide delivers actionable protocols, troubleshooting tips, and data-driven insights to optimize metabolic and renal research with APExBIO’s high-purity compound.

• Dimethoxy-Tolazoline Derivatives: Selectivity at α1/α2-Adren

  2026-04-29

  This study systematically dissects how positional dimethoxy substitution on tolazoline affects potency, selectivity, and intrinsic activity at α1- and α2-adrenoreceptors in vitro. The findings establish structural determinants for agonism and antagonism, offering a refined toolkit for probing adrenergic signaling and supporting the rational design of receptor-specific pharmacological probes.

• ASMase Drives Diabetic Cardiomyopathy via Mitochondrial Ca2+

  2026-04-29

  Wei et al. (2025) elucidate how acid sphingomyelinase (ASMase) exacerbates diabetic cardiomyopathy (DCM) by promoting mitochondrial calcium overload through MICU1 activation and enhanced ER-mitochondria contact. Their integrative mouse and cell model work identifies the ASMase-MICU1 axis as a promising therapeutic target for DCM, refining our mechanistic understanding of disease progression.

• Lysosomal β-Galactosidase Staining Kit: Enhanced Control in

  2026-04-28

  The Lysosomal β-Galactosidase Staining Kit from APExBIO sets a new benchmark for reliable, artifact-free control staining in cellular senescence workflows. This guide details optimized protocols, troubleshooting strategies, and the impact of recent mechanistic oncology insights on practical assay enhancements.

8644 records 14/577 page Previous Next First page 上5页 1112131415 下5页 Last page